PipelineReview.com7h
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
SAN DIEGO, CA, USA I 12, 2025 I AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ...
PipelineReview.com7h
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with ...
PipelineReview.com7h
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...
PipelineReview.com7h
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
NORTH CHICAGO, IL and WALTHAM, MA, USA I 12, 2025 I AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology ...
PipelineReview.com14h
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
PARIS, France I February 12, 2025 I GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...
PipelineReview.com14h
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor
LONDON, UK I 11, 2025 I Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer ...
PipelineReview.com14h
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Safety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients. CARLSBAD, CA, USA I 11, 2025 I Lineage Cell Therapeutics, Inc. (NYSE American and ...
PipelineReview.com14h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
PipelineReview.com14h
Lion TCR’s Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international ...
PipelineReview.com14h
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment ...
PipelineReview.com14h
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
PALO ALTO, CA, USA I 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...
PipelineReview.com1d
Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer
Company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end ...